(2R,3S) N1-[1,3-dihydro-1-(3-phenoxybenzyl)-2-oxo-5-(phenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(allyl)-butanediamide | 258866-03-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2R,3S) N1-[1,3-dihydro-1-(3-phenoxybenzyl)-2-oxo-5-(phenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(allyl)-butanediamide
• 英文别名: (2S,3R)-3-(2-methylpropyl)-N'-[2-oxo-1-[(3-phenoxyphenyl)methyl]-5-phenyl-3H-1,4-benzodiazepin-3-yl]-2-prop-2-enylbutanediamide
• CAS: 258866-03-4
• 化学式: C₃₉H₄₀N₄O₄
• 分子量: 628.771
• InChiKey: UJWICLFXHZHGBT-STVSUEOMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  47
• 可旋转键数：
  13
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  114
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Succinoylamino lactams as inhibitors of A-beta protein production
  申请人：Olson E. Richard

  公开号：US20050245501A1

  公开（公告）日：2005-11-03

  This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及具有药物和生物作用特性的新型内酰胺、它们的药物组合物和使用方法。这些新化合物抑制淀粉样前体蛋白的处理，更具体地抑制Aβ肽的产生，从而防止神经淀粉样蛋白沉积物的形成。更具体地，本发明涉及与β-淀粉样蛋白产生相关的神经系统疾病的治疗，例如阿尔茨海默病和唐氏综合症。
• Succinoylamino lactams as inhibitors of a-beta protein production
  申请人：Olson E. Richard

  公开号：US20060264417A1

  公开（公告）日：2006-11-23

  This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及具有药物和生物影响性质的新型内酰胺，其制药组合物和使用方法。这些新化合物抑制淀粉样前体蛋白的处理，更具体地抑制Aβ-肽的产生，从而防止神经沉积物的淀粉样蛋白的形成。更具体地，本发明涉及与β-淀粉样蛋白产生相关的神经系统疾病的治疗，例如阿尔茨海默病和唐氏综合症。
• SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION
  申请人：Olson Richard E.

  公开号：US20080293692A1

  公开（公告）日：2008-11-27

  This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及具有药物和生物影响性质的新型内酰胺、其制药组合物和使用方法。这些新化合物抑制淀粉样前体蛋白的加工，更具体地抑制Aβ肽的产生，从而防止神经沉积物的淀粉样蛋白形成。更具体地，本发明涉及与β-淀粉样蛋白产生相关的神经系统疾病的治疗，如阿尔茨海默病和唐氏综合症。
• SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP1102752B1

  公开（公告）日：2005-10-19
• US6794381B1
  申请人：——

  公开号：US6794381B1

  公开（公告）日：2004-09-21